Employers Cut GLP-1 Coverage: What to Know for 2027
Photo: Sasun Bughdaryan
As companies reassess health benefits, many are dropping GLP-1 weight-loss drugs. Here is what employees need to know about future coverage options.
The landscape for weight-loss medication coverage is shifting rapidly as we head toward 2027. In recent months, a growing number of large employers and private insurance plans have announced plans to scale back or entirely drop coverage for GLP-1 receptor agonists, such as Wegovy and Zepbound. For millions of employees who rely on these medications to manage obesity, this trend creates significant uncertainty about their future healthcare costs and access.
Employers cite the rising price tag of these drugs as the primary driver behind these decisions. Since GLP-1 medications are often prescribed as long-term treatments, the cumulative cost for a large workforce can reach millions of dollars annually. As corporate budgets tighten, many human resources departments are prioritizing cost-containment measures, leading to a reduction in high-cost specialty drug benefits.
What does this mean for the average employee? Many plans are moving toward stricter utilization management. This includes requirements for "step therapy," where patients must first try less expensive medications or behavioral interventions before qualifying for GLP-1s. Others are implementing lifetime caps on weight-loss drug benefits, or requiring higher co-pays that shift more of the financial burden onto the patient. Some companies are opting to remove weight-loss medications from their formularies entirely, maintaining coverage only for patients with a diagnosis of Type 2 diabetes.
For those currently on these medications, the 2027 benefit season requires proactive planning. Experts advise employees to review their company’s summary plan description (SPD) or talk directly with their benefits administrator during the upcoming open enrollment period. Understanding whether your plan has changed is crucial, as some policies may grandfather in existing patients while others will require a total transition to alternative treatments by the start of the new plan year.
If your employer drops coverage, you are not necessarily out of options, but you may face higher out-of-pocket expenses. Some patients may look toward health savings accounts (HSAs) or flexible spending accounts (FSAs) to cover costs if their doctor confirms medical necessity. Additionally, pharmaceutical manufacturers often offer savings cards or patient assistance programs, though eligibility for these varies significantly depending on whether you have commercial insurance or are uninsured.
Beyond medication, many employers are pivoting their wellness budgets toward comprehensive lifestyle programs. These may include access to registered dietitians, digital weight management platforms, or subsidized gym memberships. While these programs do not replace the metabolic effects of medication, they are increasingly being viewed by companies as a more sustainable long-term health investment.
As the conversation around obesity treatment continues to evolve, the gap between clinical recommendation and insurance coverage remains a major point of friction. For 2027, the focus for patients will likely be on flexibility and exploring the range of support systems available outside of traditional pharmacy benefits. Keeping clear lines of communication with your medical provider will be the most important step in navigating these changes to ensure your health outcomes remain a priority regardless of shifting insurance policies.
Consult a healthcare professional. This is not financial advice.
This article was generated based on trending topic: “GLP-1 drug coverage is being dropped by employer plans: What to know about 2027 weight-loss options - CNBC”